# Antifungal Susceptibility {-}

This section covers antifungal susceptibility testing (AFST), covering manual and automated methods, classes of antifungal agents, and intrinsic resistance patterns

## **Antifungal Susceptibility Testing (AFST)** {-}

*   **Purpose:** To determine the susceptibility of a fungal isolate to various antifungal agents, guiding appropriate therapy
*   **Importance:**
    *   Guides antifungal therapy
    *   Detects resistance
    *   Monitors resistance trends
    *   Optimizes dosing

### **Manual Methods** {-}

*   **Broth Microdilution (BMD)**
    *   **Principle:** Two-fold dilutions of antifungals in broth; MIC is the lowest concentration inhibiting growth
    *   **Advantages:** Gold standard, quantitative, versatile, inexpensive
    *   **Limitations:** Labor-intensive, subjective, expertise required
*   **Etest**
    *   **Principle:** Antifungal gradient on a strip; MIC is where the zone intersects the strip
    *   **Advantages:** Easy to perform, quantitative, versatile
    *   **Limitations:** More expensive, reading can be difficult

### **Automated Methods** {-}

*   **Examples:** Vitek 2, MicroScan, Sensititre
*   **Principle:** Automate inoculation, incubation, reading, and interpretation
*   **Advantages:** Faster, increased throughput, reduced labor, standardized
*   **Limitations:** Higher cost, limited species coverage, requires maintenance

## **Classes of Antifungal Agents** {-}

*   **Azoles**
    *   **Mechanism:** Inhibit ergosterol synthesis
    *   **Types:** Fluconazole, itraconazole, voriconazole, posaconazole, isavuconazole
    *   **Spectrum:** Broad, but varies by azole and species
    *   **Considerations:** Drug interactions, resistance, QT prolongation
*   **Polyenes**
    *   **Mechanism:** Bind to ergosterol, disrupting the cell membrane
    *   **Types:** Amphotericin B (D-AmB, lipid formulations), nystatin
    *   **Spectrum:** Broad
    *   **Considerations:** Toxicity (nephrotoxicity, infusion reactions), poor oral absorption
*   **Echinocandins**
    *   **Mechanism:** Inhibit beta-1,3-glucan synthesis
    *   **Types:** Caspofungin, micafungin, anidulafungin
    *   **Spectrum:** *Candida*, *Aspergillus*
    *   **Considerations:** Limited spectrum, IV only, resistance in *C. glabrata*
*   **Allylamines**
    *   **Mechanism:** Inhibit squalene epoxidase
    *   **Types:** Terbinafine, naftifine
    *   **Spectrum:** Dermatophytes
    *   **Considerations:** Limited to dermatophytes, hepatotoxicity
*   **Flucytosine (5-FC)**
    *   **Mechanism:** Inhibits DNA and RNA synthesis
    *   **Spectrum:** *Cryptococcus*, *Candida*, some molds
    *   **Considerations:** Resistance, bone marrow suppression, hepatotoxicity
*   **Griseofulvin**
    *   **Mechanism:** Disrupts microtubule function
    *   **Spectrum:** Dermatophytes
    *   **Considerations:** Limited to dermatophytes, long duration, drug interactions

## **Intrinsic Resistance Patterns** {-}

*   **Definition:** Inherent resistance due to genetic makeup, not prior exposure
*   **Examples**
    *   ***Candida krusei***: Fluconazole
    *   ***Candida glabrata***: Reduced azole susceptibility
    *   ***Candida auris***: Variable, often multidrug-resistant
    *   ***Scedosporium spp.***: Amphotericin B, many azoles
    *   ***Fusarium spp.***: Amphotericin B, many azoles
    *   ***Mucorales***: Voriconazole
*   **Importance**
    *   Guides initial therapy
    *   Avoids ineffective agents
    *   Prevents treatment failure
    *   Guides antifungal stewardship
*   **Laboratory Considerations**
    *   Perform AFST on significant isolates
    *   Follow quality control procedures
    *   Report results accurately with interpretive comments
    *   Communicate about intrinsic resistance patterns